AHCO Quote, Financials, Valuation and Earnings

Electromed has a net margin of 3.83% compared to AdaptHealth's net margin of 10.05%. AdaptHealth's return on equity of -13.93% beat Electromed's return on equity of 15.62%.

AdaptHealth has a consensus price target of $11.85, signalling upside risk potential of 13.32%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 11.56%. Given that AdaptHealth has higher upside potential than Electromed, analysts believe AdaptHealth is more attractive than Electromed.

AdaptHealth has a beta of 1.104, which suggesting that the stock is 10.399% more volatile than S&P 500. In comparison Electromed has a beta of 0.285, suggesting its less volatile than the S&P 500 by 71.506%.

AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

AdaptHealth quarterly revenues are $597.5M, which are larger than Electromed quarterly revenues of $14.7M. AdaptHealth's net income of $22.9M is higher than Electromed's net income of $1.5M. Notably, AdaptHealth's price-to-earnings ratio is -- while Electromed's PE ratio is 41.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.41x versus 4.62x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX has a net margin of 3.83% compared to AdaptHealth's net margin of -16.69%. AdaptHealth's return on equity of -13.93% beat IRIDEX's return on equity of -157.91%.

AdaptHealth has a consensus price target of $11.85, signalling upside risk potential of 13.32%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 14.94%. Given that IRIDEX has higher upside potential than AdaptHealth, analysts believe IRIDEX is more attractive than AdaptHealth.

AdaptHealth has a beta of 1.104, which suggesting that the stock is 10.399% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.812, suggesting its less volatile than the S&P 500 by 18.837%.

AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

AdaptHealth quarterly revenues are $597.5M, which are larger than IRIDEX quarterly revenues of $11.6M. AdaptHealth's net income of $22.9M is higher than IRIDEX's net income of -$1.9M. Notably, AdaptHealth's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.41x versus 0.59x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of 3.83% compared to AdaptHealth's net margin of -10.5%. AdaptHealth's return on equity of -13.93% beat Myomo's return on equity of -84.04%.

AdaptHealth has a consensus price target of $11.85, signalling upside risk potential of 13.32%. On the other hand Myomo has an analysts' consensus of $7.04 which suggests that it could grow by 19.42%. Given that Myomo has higher upside potential than AdaptHealth, analysts believe Myomo is more attractive than AdaptHealth.

AdaptHealth has a beta of 1.104, which suggesting that the stock is 10.399% more volatile than S&P 500. In comparison Myomo has a beta of 1.709, suggesting its more volatile than the S&P 500 by 70.858%.

AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

AdaptHealth quarterly revenues are $597.5M, which are larger than Myomo quarterly revenues of $9.2M. AdaptHealth's net income of $22.9M is higher than Myomo's net income of -$966.4K. Notably, AdaptHealth's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.41x versus 9.38x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of 3.83% compared to AdaptHealth's net margin of -67.31%. AdaptHealth's return on equity of -13.93% beat Stereotaxis's return on equity of -108.68%.

AdaptHealth has a consensus price target of $11.85, signalling upside risk potential of 13.32%. On the other hand Stereotaxis has an analysts' consensus of -- which suggests that it could grow by 92.31%. Given that Stereotaxis has higher upside potential than AdaptHealth, analysts believe Stereotaxis is more attractive than AdaptHealth.

AdaptHealth has a beta of 1.104, which suggesting that the stock is 10.399% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.570, suggesting its more volatile than the S&P 500 by 57.046%.

AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

AdaptHealth quarterly revenues are $597.5M, which are larger than Stereotaxis quarterly revenues of $9.2M. AdaptHealth's net income of $22.9M is higher than Stereotaxis's net income of -$6.2M. Notably, AdaptHealth's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.41x versus 7.83x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.